Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 2—February 2011
Dispatch

Pandemic (H1N1) 2009–associated Pneumonia in Children, Japan

Maki Hasegawa, Takafumi Okada, Hiroshi Sakata, Eiichi Nakayama, Tatsuo Fuchigami, Yasuji Inamo, Hideo Mugishima, Takeshi Tajima, Satoshi Iwata, Miyuki Morozumi, Kimiko Ubukata, Haruo Watanabe, and Takashi TakahashiComments to Author 
Author affiliations: Author affiliations: Kitasato University, Tokyo (M. Hasegawa, T. Okada, E. Nakayama, M. Morozumi, K. Ubukata, T. Takahashi); Nihon University School of Medicine, Tokyo, Japan (M. Hasegawa, T. Fuchigami, Y. Inamo, H. Mugishima); National Hospital Organization Tokyo Medical Center, Tokyo (T. Okada, S. Iwata); Asahikawa-Kosei General Hospital, Asahikawa, Japan (H. Sakata); Komagome Hospital, Tokyo (E. Nakayama); Hakujikai Memorial Hospital, Tokyo (T. Tajima); National Institute of Infectious Diseases, Tokyo (H. Watanabe)

Main Article

Table 1

Demographic characteristics and clinical features of children hospitalized with pandemic (H1N1) 2009–associated pneumonia, Japan, August–November 2009*

Variable Total Group A, no complications, n = 63 Group B, complications, n = 17 p value, A vs. B
Sex, M/F
 57 (71.3)/23 (28.8)
 46 (73.0)/17 (27.0)
 11 (64.7)/6 (35.3)
 0.71
Median age, y (range) 7 y (9 mo–14y) 7 y (9 mo–14 y) 6 y (4 y–12 y) 0.41
<1 y 4 (5) 4 (6.3) 0
2–5 y 14 (17.5) 11 (17.5) 3 (17.6)
>6 y
 62 (77.5)
 48 (76.2)
 14 (82.3)
History of asthma
 26 (32.5)
 21 (33.3)
 5 (29.4)
 0.76
Admission <3 d/>4 d after symptom onset
 61 (76.3)/19 (23.8)
 45 (71.4)/18 (28.6)
 16 (94.1)/1 ( 5.9)
 0.10
Major symptoms, physical findings
Cough 66 (82.5) 53 (84.1) 13 (76.5) 0.71
Respiratory distress 29 (36.3) 17 (27.0) 12 (70.6) <0.01
Fever >38°C 74 (92.5) 58 (92.1) 16 (94.1) 0.53
Tachypnea 57 (71.3) 42 (66.6) 15 (88.2) 0.15
Inspiratory retraction 39 (48.8) 27 (42.9) 12 (70.6) 0.04
Rhonchi 48 (60.0) 40 (63.5) 8 (47.1) 0.22
 SpO2 <93
 39 (48.8)
 25 (39.7)
 14 (82.4)
 <0.01
Treatment and clinical course
O2 supplementation 49 (61.3) 34 (54.0) 15 (88.2) 0.01
Mean duration of O2 administration, d
(range) 3.5 (1–11) 2.9 (1–6) 4.7 (1–11) 0.02
Treatment with oseltamivir 67 (83.8) 51 (80.9) 16 (94.1) 0.35
Treatment with antimicrobial drugs† 63 (78.8) 46 (73.0) 17 (100) 0.04
Isoproterenol inhalation
 6 (7.5)
 0
 6 (35.3)
 <0.01
Median duration of hospitalization, d (range) 6 (3–18) 6 (3–9) 8 (5–18) <0.01

*Values are no. (%) except as indicated. SpO2, percutaneous oxygen saturation while breathing room air.
†Parenteral infusion of sulbuctum/ampicillin or cefazoin was carried out for 3–5 d.

Main Article

Page created: July 08, 2011
Page updated: July 08, 2011
Page reviewed: July 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external